<DOC>
	<DOCNO>NCT00200512</DOCNO>
	<brief_summary>The objective study measure continue efficacy apomorphine previous exposure least three month duration .</brief_summary>
	<brief_title>Continued Efficacy Apomorphine After Previous Exposure Least Three Months</brief_title>
	<detailed_description>This prospective , double-blind , randomize , placebo-controlled , crossover desigh , multicenter study safety effectiveness subcutaneous apomorphine treatment . Patients receive apomorphine placebo , randomize double-blind fashion</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Patients diagnose idiopathic Parkinson 's Disease classify stage IIIV Hoehn Yahr scale stag severity Parkinson 's Disease Patients must optimally maximize oral therapy regimen include levodopa/decarboxylase inhibitor either immediate delayed release form , plus least one direct act oral dopamine agonist least 30 day prior randomization Patients must receive apomorphine subcutaneous injection rescue therapy `` Off '' event least three month average dosing requirement least 2 dos per day week prior enrollment dose less 11 mg Patients medical therapy clinically significant psychosis dementia relate ingestion antiparkinson medication . ( Patients hallucination central adverse reaction associate solely antiparkinson medication exclude . ) Patients history drug alcohol dependency within one year prior study enrollment Patients unstable clinically significant disease cardiovascular ( include orthostatic hypotension ) , hematologic ( include Coombs ' positive hemolytic anemia ) , hepatic , renal , metabolic , respiratory , gastrointestinal endocrinological system neoplasm within threemonths start study . Patients history allergy intolerance morphine derivative , sulfur , sulfur contain medication , sulfites , domperidone , trimethobenzamide anticholinergic . Patients treat experimental agent ( apomorphine intermittent subcutaneous injection ) within 3 month study entry , experimental agent define basis regulatory status country patient observation , disallow medication Patients whose apomorphine regimen characterize continuous infusion administration method intermittent subcutaneous injection . Patients could would sign informed consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2000</verification_date>
</DOC>